Engineering probiotics for mucosal vaccination: from the Escherichia coli Nissle 1917 paradigm to a translational vaccine platform
Frontiers in Gastroenterology · 29.10.2026 · 5
DOI: 10.3389/fgstr.2026.1980209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Gastroenterology, online erschienen am 29.10.2026. Verfasst von Irene Palenca und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neuropharmacology and Behavioral Science Laboratory, Santa Lucia Foundation (IRCCS Fondazione Santa Lucia), Rome, Italy. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mucosal vaccination is attracting renewed interest because many clinically relevant pathogens first encounter the host at gastrointestinal or respiratory surfaces, whereas most established vaccines are administered parenterally and are optimized primarily to induce systemic immunity. Engineered probiotics are emerging as living antigen-delivery vectors that may combine mucosal delivery, transient biological persistence, microbial immune signals, and programmable antigen presentation within a single platform. This strategy is particularly relevant to gastrointestinal vaccination, where access to gut-associated lymphoid tissue (GALT) may support local secretory IgA together with systemic responses. SARS-CoV-2 provides an informative experimental bridge because, despite its dominant respiratory manifestations, it can involve intestinal epithelial cells and gastrointestinal mucosal immunity. Using the pAIDA–Escherichia coli Nissle 1917 (EcN) system as a bounded proof of concept, this Perspective defines an integrated translational framework linking GALT-directed immune priming, effective mucosal antigen dose, genetic stability, chassis de-risking, biocontainment, manufacturing, potency, and post-administration clearance. We explicitly distinguish antigen delivery and immunogenicity from functional immunity, protection, and clinical efficacy, and identify the experiments required to advance probiotic-vectored mucosal vaccines toward clinically testable products.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuropharmacology and Behavioral Science Laboratory, Santa Lucia Foundation (IRCCS Fondazione Santa Lucia), Rome, Italy.
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy.
- Nextbiomics S.R.L., Naples, Italy.
- Department of Clinical Medicine and Surgery, "Federico II" University of Naples, Naples, Italy.
Zitieren
APA
Palenca, I., Esposito, G., Pesce, M., & Sarnelli, G. (2026). Engineering probiotics for mucosal vaccination: from the Escherichia coli Nissle 1917 paradigm to a translational vaccine platform. Frontiers in Gastroenterology, 5. https://doi.org/10.3389/fgstr.2026.1980209
Vancouver
Palenca I, Esposito G, Pesce M, Sarnelli G. Engineering probiotics for mucosal vaccination: from the Escherichia coli Nissle 1917 paradigm to a translational vaccine platform. Frontiers in Gastroenterology. 2026;5. doi:10.3389/fgstr.2026.1980209
BibTeX
@article{Palenca2026,
author = {Palenca, Irene and Esposito, Giuseppe and Pesce, Marcella and Sarnelli, Giovanni},
title = {Engineering probiotics for mucosal vaccination: from the Escherichia coli Nissle 1917 paradigm to a translational vaccine platform},
journal = {Frontiers in Gastroenterology},
year = {2026},
volume = {5},
doi = {10.3389/fgstr.2026.1980209}
}
EUVIMED